Searchable abstracts of presentations at key conferences in endocrinology

ea0056gp147 | Neuroendocrinology | ECE2018

Macrophages involvement in neuroendocrine tumor behaviour and progression

Boemi Ilena , Vitali Eleonora , Veronesi Giulia , Zerbi Alessandro , Lania Andrea

Neuroendocrine tumors (NETs) are rare neoplasms showing a wide spectrum of clinical behaviors. The therapeutic options available for NET treatment are rarely curative and most are palliative, as NETs frequently show resistance to pharmacological therapy. Cancers develop in complex tissue environments, which they depend upon for sustained growth, invasion and metastasis. A major characteristic of the tumor microenvironment is inflammatory cell infiltration, where tumor-associat...

ea0049oc7.4 | Cardiovascular endocrinology (1) | ECE2017

A novel insight into the anticancer mechanism of metformin in Pancreatic Neuroendocrine Tumor cells

Vitali Eleonora , Piccinini Sara , Boemi Ilena , Tresoldi Alberto , Zerbi Alessandro , Carnaghi Carlo , Spada Anna , Lania Andrea

Metformin (1.1-dimethylbiguanide hydrochloride), a widely used antidiabetic drug, has been reported to display potent anticancer properties in various types of cancers, including neuroendocrine tumors. Recently, a potential synergistic activity between metformin and octreotide (SSA) in Pancreatic Neuroendocrine Tumors (P-NETs) has been proposed. AIP (aryl hydrocarbon receptor-interacting protein) acts as tumor suppressor gene in neuroendocrine tumors at pituitary level and it ...

ea0070aep563 | Pituitary and Neuroendocrinology | ECE2020

Macrophages involvement in neuroendocrine tumor behaviour and progression

Boemi Ilena , Vitali Eleonora , Trivellin Giampaolo , Smiroldo Valeria , Lavezzi Elisabetta , Zerbi Alessandro , Stratakis Constantine , Lania Andrea

Neuroendocrine neoplasms (NENs) are rare tumour showing a wide spectrum of clinical behaviours. Therapeutic options available for NET treatment are rarely curative and mostly palliative, as NETs frequently show resistance to pharmacological therapy. Cancers develop in complex tissue environments, which they depend on. Tumour-associated macrophages (TAMs) are a major cellular component of the tumour microenvironment. Two polarized state of macrophages are described in literatur...

ea0037gp.28.05 | Endocrine tumours and neoplasia – NETS | ECE2015

Filamin-A is involved in stabilisation, signal transduction, and angiogenesis regulation mediated by somatostatin receptor 2 in pancreatic neuroendocrine tumors

Vitali Eleonora , Cambiaghi Valeria , Loiarro Federica , Zerbi Alessandro , Colombo Piergiuseppe , Spada Anna , Mantovani Giovanna , Peverelli Erika , Carnaghi Carlo , Lania Andrea

Somatostatin receptor type 2 (SST2) is the main pharmacological target of long-acting somatostatin analogues (SSA) widely used in patients with pancreatic neuroendocrine tumours (P-NETs). A subset of patients is resistant to SSA, although the molecular mechanisms responsible for resistance are poorly understood. Several studies identified cytoskeleton protein interactions as determinant in receptor anchoring, expression and signalling. Since SST2 was recently demonstrated to a...

ea0035p517 | Endocrine tumours and neoplasia | ECE2014

The effects of cAMP in different neuroendocrine tumorous cells: the role of Epac and PKA in cell proliferation and cell adhesion

Vitali Eleonora , Cambiaghi Valeria , Zerbi Alessandro , Peverelli Erika , Mantovani Giovanna , Loiarro Federica , Carnaghi Carlo , Spada Anna , Lania Andrea

cAMP is an ubiquitous second messenger that is implicated in the regulation of a wide variety of cell functions, including cell proliferation that is differently affected depending on the cell type. Although the effects exerted by cAMP were initially attributed to PKA activation, two exchange proteins directly activated by cAMP (Epac1/2) have been identified as cAMP targets able to mediate several cAMP effects. Aim of this study was to investigate the effect of cAMP on neuroen...

ea0070aep724 | Pituitary and Neuroendocrinology | ECE2020

Metformin and everolimus: A promising combination for neuroendocrine tumors treatment

Vitali Eleonora , Boemi Ilena , Piccini Sara , Tarantola Giulia , Zerbi Alessandro , Smiroldo Valeria , Lavezzi Elisabetta , Spada Anna , Mantovani Giovanna , Lania Andrea

Treatment options for neuroendocrine tumors (NET), including everolimus, are rarely curative, as NETs frequently show resistance to medical therapy. In fact, the use of everolimus, an mTOR inhibitor, is limited by the development of resistance, probably due to the activation of Akt signalling. Metformin seems to have anticancer effects in neuroendocrine tumors (NETs). A recent retrospective study found longer progression-free-survival in diabetic pancreatic neuroendocrine tumo...

ea0098c51 | Clinical – Surgery/Applied Pathology | NANETS2023

A prospective phase ii single-arm trial on neoadjuvant peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE followed by surgery for pancreatic neuroendocrine tumors (NeoLuPaNET)

Partelli Stefano , Landoni Luca , Bartolomei Mirco , Zerbi Alessandro , Maria Grana Chiara , Boggi Ugo , Butturini Giovanni , Casadei Riccardo , Bassi Claudio , Falconi Massimo

Background: Surgical resection of Nonfunctioning Pancreatic Neuroendocrine Tumor (NF-PanNET) is curative in most of the cases. Neoadjuvant treatments in patients with resectable NF-PanNET at high-risk of recurrence have never been investigated. Aim of this study was to test the safety and efficacy of neoadjuvant PRRT with 177Lu-DOTATATE followed by surgery in patients with resectable high-risk NF-PanNET.Methods: This was a multi-center single-...